ResMed Inc (RMD)

Return on equity (ROE)

		Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019
Net income (ttm)	US$ in thousands	1,020,950	958,378	890,386	906,500	897,556	862,953	809,465	786,302	779,437	779,476	521,983	499,746	474,505	457,240	698,858	679,898	621,674	512,640	454,919	419,004
Total stockholders’ equity	US$ in thousands	4,864,040	4,629,920	4,481,850	4,250,380	4,129,900	3,932,510	3,738,130	3,432,890	3,360,750	3,278,800	3,145,840	3,026,050	2,885,680	2,709,230	2,864,980	2,678,860	2,497,030	2,256,430	2,258,110	2,117,250
ROE		20.99%	20.70%	19.87%	21.33%	21.73%	21.94%	21.65%	22.90%	23.19%	23.77%	16.59%	16.51%	16.44%	16.88%	24.39%	25.38%	24.90%	22.72%	20.15%	19.79%

June 30, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $1,020,950K ÷ $4,864,040K
= 20.99%

ResMed Inc has shown a relatively stable trend in its return on equity (ROE) over the past few quarters, with ROE ranging from 16.44% to 25.38%. The ROE for the most recent quarter, Jun 30, 2024, was 20.99%, indicating that for every dollar of shareholders' equity, the company generated a profit of $0.2099.

The company's ROE has generally remained above 20% over the past few quarters, reflecting a strong ability to generate profits from its shareholders' equity. This indicates that ResMed is efficiently utilizing its equity to generate earnings for its shareholders.

The slight fluctuations in ROE over the quarters may be attributed to changes in the company's profitability, asset management efficiency, and financial leverage. Investors and analysts typically view a consistent and high ROE positively, as it signifies a strong and efficient use of capital.

Overall, ResMed's ROE performance suggests that the company has been successful in generating value for its shareholders through effective management of its assets and operations. It will be essential to monitor future quarters to assess the company's ability to maintain and potentially improve its ROE levels.